A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Sponsor

Novartis Pharmaceuticals (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05976243

Collaborator

(none)

348

Enrollment

Arms

60.4

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE).

The purpose of the core period (52 weeks of treatment) of this study is to evaluate the efficacy, safety, and tolerability of remibrutinib (LOU064) vs. placebo in adults suffering from CINDU inadequately controlled by H1-antihistamines (H1-AHs).

The purpose of the OLE period is to collect long-term efficacy, safety, and tolerability data on remibrutinib in participants after having completed the Core period

Condition or Disease	Intervention/Treatment	Phase
Chronic Inducible Urticaria	Drug: Remibrutinib Other: Placebo	Phase 3

Detailed Description

This study consists of a core and extension periods.

The Core period (6 arms) has a total duration of up to 60 weeks including a double-blind placebo-controlled treatment period until Week 24 followed by open-label treatment with remibrutinib up to Week 52. The primary endpoint for all CINDU subtypes is assessed at Week 12.

The Core period consists of:

Screening period (up to 4 weeks): During the screening period, participants who have provided informed consent will be assessed for study eligibility.
Double-blind, placebo-controlled treatment period (24 weeks): 24 weeks of double-blind treatment with remibrutinib or placebo.
Open-label treatment period (28 weeks): 28 weeks of open-label treatment with remibrutinib.
Follow-up period: 4 weeks of treatment free follow-up. The open-label extension period consists of observation and treatment period. At the end of the core period of the study, if participants continue to experience symptoms, they will transition to the treatment period in OLE. If they do not experience symtpoms they will transition to the observation period in the OLE.

The duration of the Open-label Extension period will be approximately 3 years where participants can switch from observation to treatment depending on if they start developing symptoms. Only those participants participating in the Open-label Extension Treatment period will receive remibrutinib. The participants in the Open-label Extension Observation period will not receive remibrutinib

Study Design

Study Type:

Interventional

Anticipated Enrollment :

348 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Triple (Participant, Investigator, Outcomes Assessor)

Masking Description:

This masking applies to the core period. There is no masking in the open-label extension (OLE).

Primary Purpose:

Treatment

Official Title:

A 52-week Multi-center, Randomized, Double-blind, Placebo Controlled, Basket Study With an Open-label Extension to Investigate the Efficacy, Safety, and Tolerability of Remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in Adults Inadequately Controlled by H1-antihistamines

Anticipated Study Start Date :

Dec 19, 2023

Anticipated Primary Completion Date :

Jul 8, 2026

Anticipated Study Completion Date :

Dec 31, 2028

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Remibrutinib, symptomatic dermographism group Remibrutinib oral twice daily in participants with symptomatic dermographism	Drug: Remibrutinib Remibrutinib treated groups and arms
Placebo Comparator: Placebo, symptomatic dermographism group Placebo oral twice daily, symptomatic dermographism	Other: Placebo Placebo treated groups and arms
Experimental: Remibrutinib, cold urticaria group Remibrutinib oral twice daily, cold urticaria	Drug: Remibrutinib Remibrutinib treated groups and arms
Placebo Comparator: Placebo, cold urticaria group Placebo oral twice daily, cold urticaria	Other: Placebo Placebo treated groups and arms
Experimental: Remibrutinib, cholinergic urticaria group Remibrutinib oral twice daily, cholinergic urticaria	Drug: Remibrutinib Remibrutinib treated groups and arms
Placebo Comparator: Placebo, cholinergic urticaria Placebo oral twice daily, cholinergic urticaria	Other: Placebo Placebo treated groups and arms

Outcome Measures

Primary Outcome Measures

Proportion of participants with complete response in Total Fric Score; symptomatic dermographism [Week 12]
Total Fric score (a scale from 0-4 where a positive response with all of the four pins is TFS = 4, while a positive response with only one pin - the largest pin is TFS = 1)
Proportion of participants with complete response in critical temperature threshold; cold urticaria [Week 12]
The Temptest is used to induce itch and hives in participants with cold urticaria. Critical temperature threshold (CTT), as measured by the Temptest, determines the highest temperature that induces symptoms.
Proportion of participants with itch numerical rating scale =0; cholinergic urticaria [Week 12]
Itch numerical rating scale, a scale from 0 to 10 Patients are asked to rate itching severity based on the worst level of itching in the past 24 h using an 11-point scale from 0 ("no itch") to 10 ("worst itch imaginable")

Secondary Outcome Measures

Change from baseline in Total Fric score; symptomatic dermographism [Week 12]
Total Fric score, a scale from 0-4 where a positive response with all four pins is TFS=4, while a positive only 1 pin - the largest pin is TFS=1
Change from baseline in criticial temperature threshold following Temptest; cold urticaria [Week 12]
Critical temperature threshold, as measured by the Temptest, determines the highest temperature that induces symptoms
Change from baseline in itch numerical rating scale; cholinergic urticaria [Week 12]
Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").
proportion of participants with Physician Global Assessment (PGA) severity of hives =0; cholinergic urticaria [Week 12]
Physician global assessment of severity of hives. This assessment is scored 0 to 4 with 0=no hives, 1=mild hives, 2=moderate hives, 3=severe hives and 4=very severe hives
Proportion of participants with complete response in TFS; symptomatic dermographism [Week 24]
Total Fric score (a scale from 0-4 where a positive response with all of the four pins is TFS = 4, while a positive response with only one pin - the largest pin is TFS = 1)
Proportion of participants with complete response in Critical Temperature threshold; cold urticaria [Week 24]
Critical Temperature Threshold, as measured by the Temptest, is the highest temperature that induces symptoms
Proportion of participants with complete response in itch numerical rating scale; cholinergic urticaria [Week 24]
Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").
Change from baseline in itch numerical rating scale in participants with symptomatic dermographism [Week 12]
Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").
Change from baseline in itch numerical rating scale in participants with cold urticaria [Week 12]
Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").
Proportion of participants with complete response in Total Fric score; symptomatic dermographism [Week 2]
Total Fric score (a scale from 0-4 where a positive response with all of the four pins is TFS = 4, while a positive response with only one pin - the largest pin is TFS = 1)
Proportion of participants with complete response in Critical Temperature Threshold; cold urticaria [Week 2]
Critical temperature threshold (CTT), as measured by the Temptest, determines the highest temperature that induces symptoms.
Proportion of participants with itch NRS=0; cholinergic urticaria [Week 2]
Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").
Change from baseline in TFS in participants with symptomatic dermographism [Week 2]
Total Fric score (a scale from 0-4 where a positive response with all of the four pins is TFS = 4, while a positive response with only one pin - the largest pin is TFS = 1)
Change from baseline in Critical Temperature Threshold in participants with cold urticaria [Week 2]
Critical temperature threshold (CTT), as measured by the Temptest, determines the highest temperature that induces symptoms.
Change from baseline in itch NRS in participants with cholinergic urticaria [Week 2]
Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").
Change from baseline in itch NRS in participants with symptomatic dermographism [Week 2]
Total Fric score (a scale from 0-4 where a positive response with all of the four pins is TFS = 4, while a positive response with only one pin - the largest pin is TFS = 1)
Change from baseline in itch NRS in participants with cold urticaria [Week 2]
Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").
Proportion of participants with cholinergic urticaria with PGA=0 [Week 2]
Physician global assessment of severity of hives is a 4-point scale (0 = no active disease, 1 = mild disease, 2 = moderate disease, 3 = severe disease).
Change from baseline in weekly most bothersome symptom NRS score on the USDD [Week 12]
Urtricara symptom daily diary (USDD). This daily diary records if the participant experiences any symptoms or avoided the triggers
Proportion of participants with DLQI=0-1 [Week 12]
The Dermatology Life Quality Index (DLQI) is a 10-item dermatology-specific quality of life (QoL) measure. Subjects rate their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days. An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease-related QoL). A DLQI score of 0 or 1 means that there is no impact of a skin disease on the patient's life.
Occurrence of treatment emergent adverse events and serious adverse events during the study [Week 52]
Treatment emergent adverse events and serious adverse events are those that occur at any time only after treatment has started

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria for core period:

Male and female participants ≥18 years of age at the time of signing of the ICFs
Confirmed CINDU diagnosis (as per guidelines) for symptomatic dermographism, cold urticaria or cholinergic urticaria for ≥ 4 months (defined as onset of CINDU with supporting documentation (e.g medical record, clinical history, photographs)) and inadequate control with H1-AH at local label approved doses at the time of randomization
The following response to the provocation test for each subtype is required at the randomization visit :

Symptomatic Dermographism: A Total Fric Score of ≥3 using the FricTest® 4.0 and a numerical rating scale score of ≥5 for itch after the provocation test.
Cold Urticaria: A Critical Threshold Temperature of ≥15°C using the TempTest® 4.0 and a numerical rating scale score of ≥5 for itch after the provocation test.
Cholinergic Urticaria: A physician global assessment of severity of hives ≥ 2 using the Pulse-controlled ergometry test and a numerical rating scale score of ≥5 for itch after the provocation test.

Cold Urticaria: Positive ice-cube test resulting in hives at the provocation site for participants at Screening.
Cholinergic urticaria: Participants must show sweating in performing the pulse-controlled ergometry test on day of randomization. Participants with anhidrosis must not be included.

Inclusion criteria for the OLE:

Participants who have completed the Core period up to Week 52 and are willing to enter the OLE period

Exclusion Criteria for core period:

1. Previous use of remibrutinib or other BTK inhibitors.

Participants who have concomitant CSU at screening. Participants with resolved CSU at the time of screening can be included in the study.
Participants who have a familial form (e.g familial cold autoinflammatory syndrome, familial cold urticaria) of the target CINDU that is being considered for the participant's inclusion in this study.
Participants having a more defined other form of inducible urticaria than the target CINDU that is being considered for the participant's inclusion in this study.
Diseases, other than chronic inducible urticaria, with urticaria or angioedema symptoms including but not limited to urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa) and hereditary or acquired angioedema
Any other skin disease associated with chronic itching that might influence, in the investigator's opinion, the study evaluations and results (e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, etc.) or skin diseases associated with only wheals and no itch e.g asymptomatic dermographism

There are no exclusion criteria for OLE